Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammator, Allergic Conditions”  or 3TR is the largest immunology project of the Innovative Medicines Initiative (IMI2). It aims at improving our knowledge of how patients with allergic and inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), respond to treatments, and at ways to enhance personalised therapies. EFA brings the patients’ perspective to 3TR through the coordination of an adult and paediatric 3TR Respiratory Patient Working Group (PWG).

3TR group photo Amsterdam

The PWG took part in the two stages of a Definition of Response study. Firstly, they decided how much patients improved or not by taking biological treatments. This step helped to create standard definitions for deleterious, non-response, sufficient, substantial and super response to treatment. Secondly, they weighted different levels of response in different outcome measures, both individually and against each other. This analysis helped establishing a score for each outcome measure that clinicians and researchers can easily use to assess response and non-response to the use of biologics in severe asthma treatment.

3TR photo 1 from website

3TR photo 2 from website

The PWG also helped finalise the manuscript and a communication strategy for a Core Outcome Measure Set for severe asthma (COMSA) the 3TR project developed in 2021. In addition to the work with the PWG, in October EFA attended the General Assembly of the 3TR in Amsterdam (the Netherlands), where we facilitaed a patient roundtable aimed at evaluating the state of patient engagement across the project and identifying areas for improvement.

3TR: diagnosis and treatment for Atopic Eczema

  • Consortium : 69 Partners
  • Countries: Belgium, Croatia, Denmark, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom

Research with an EFA led Respiratory Patient Working Group (PWG) of 44 individuals, 5 among whom are focused on Paediatric asthma.

Funded by Innovative Medicines Initiative (IMI2) No 831434

1 September 2019 – 31 August 2026 - 84 months

Website / X (Twitter)